More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.30B
EPS
-0.43
P/E ratio
--
Price to sales
266.73
Dividend yield
--
Beta
1.343988
Previous close
$4.06
Today's open
$4.08
Day's range
$3.93 - $4.10
52 week range
$3.46 - $7.30
show more
CEO
Sean P. Nolan
Employees
99
Headquarters
Dallas, TX
Exchange
Nasdaq Global Select
Shares outstanding
326045530
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Taysha Gene Therapies Q3 Earnings Call Highlights
Taysha Gene Therapies NASDAQ: TSHA expects to report pivotal trial data for its experimental Rett syndrome gene therapy TSHA-102 and provide feedback from U.S. regulators on a potential filing pathway in the first half of 2027, executives said on the company's third-quarter earnings call.
MarketBeat • Nov 12, 2026

Taysha Gene Therapies, Inc. (TSHA) Q3 2026 Earnings Call Transcript
Taysha Gene Therapies, Inc. ( TSHA ) Q3 2026 Earnings Call November 12, 2026 8:30 AM EST Company Participants Sean Nolan - CEO & Chairman Sukumar Nagendran - President, Head of Research & Development and Director Kamran Alam - CFO & Corporate Secretary Fred Porter - Chief of Staff & Technical Operations Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Elizabeth Webster - Goldman Sachs Group, Inc., Research Division Biren Amin - Piper Sandler & Co., Research Division Wesley Yon - BofA Securities, Research Division Maurice Raycroft - Jefferies LLC, Research Division Gil Blum - Needham & Company, LLC, Research Division Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Evan Seigerman - BMO Capital Markets Equity Research Silvan Tuerkcan - Citizens JMP Securities, LLC, Research Division Angela Qian - Canaccord Genuity Corp., Research Division Presentation Operator Thank you for standing by, and welcome to Taysha Gene Therapies Third Quarter 2026 Financial Results Conference Call.
Seeking Alpha • Nov 12, 2026

Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update
REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submission pathway in 1H 2027
GlobeNewsWire • Nov 12, 2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on November 2, 2026, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, restricted stock units (RSUs) representing 25,000 shares of the Company's common stock in connection with their employment. The RSUs were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewsWire • Nov 6, 2026

Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
DALLAS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2026, and host a corporate update conference call and webcast on Thursday, November 12, 2026, at 8:30 AM Eastern Time. Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha's website at ir.tayshagtx.com.
GlobeNewsWire • Nov 5, 2026

Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced multiple encore presentations supporting its TSHA-102 program in clinical evaluation for Rett syndrome at the 55th Child Neurology Society Annual Meeting, taking place in Montréal, Québec, Canada, from October 14 – 17, 2026. The presentations will highlight data previously shared at the 2026 International Rett Syndrome Foundation (IRSF) Scientific Meeting.
GlobeNewsWire • Oct 1, 2026

Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval
Taysha Gene Therapies offers a speculative opportunity, hinging on durable clinical gains, safety, and disciplined execution for TSHA-102 in Rett syndrome. TSHA's $455.4M cash runway extends into H2 2028, supporting pivotal data collection and manufacturing scale-up without immediate dependence on accelerated regulatory filing. TSHA-102's early data show deepening, durable functional gains in Rett patients, but pivotal efficacy, safety, and manufacturing qualification remain key investment inflection points.
Seeking Alpha • Sep 11, 2026

These 3 Risky Stocks Could Be Sitting on 100% Upside
With industrials, energy, and tech stocks undergirding an S&P 500 that is hovering near all-time highs, investors looking for high-upside companies may be resigned to more speculative plays. While it's true that some long-established firms have posted surprising rallies in recent trading sessions, a combination of consumer reticence and stretched valuations means that many go-to investments may not see much near-term growth.
MarketBeat • Sep 7, 2026

Taysha Gene Therapies Q2 Earnings Call Highlights
Taysha Gene Therapies NASDAQ: TSHA said it completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, while preparing for a potential biologics license application submission.
MarketBeat • Aug 12, 2026

Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript
Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript
Seeking Alpha • Aug 12, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Taysha Gene Therapies Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.